Open AccessA magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first‐line HAART (the INCA trial)
Author(s) -
Izzo I,
Albini L,
Calabresi A,
Motta D,
Bellagamba R,
Fezza R,
Narciso P,
Sighinolfi L,
Maggi P,
Focà E,
Mendeni M,
Manili L,
Magoni M,
Carosi G,
QuirosRoldan E,
Torti C
Publication year - 2010
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.1186/1758-2652-13-s4-p85
Subject(s) - atazanavir , efavirenz , emtricitabine , medicine , ritonavir , tenofovir , virology , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , viral load
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK